Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Management of the Patient with Stable Ischemic Heart Disease and Preserved Left Ventricular Systolic Function

Slide: 18 of 21

Patient Followup

 

After reviewing the evidence presented in the Clinician's Guide titled, Adding ACEIs and/or ARBs to Standard Therapy for Stable Ischemic Heart Disease: Benefits and Harms, which medication is an acceptable alternative for a patient with stable ischemic heart disease with preserved left ventricular systolic function who is intolerant to an ACEI?

Discussion of answers:

A. Incorrect. Beta-blockers, aspirin, and alpha-blockers are not acceptable alternatives to an ACEI.

B. Correct. Evidence from the TELMISARTAN trial indicates that a majority of patients who were intolerant to ACEIs were intolerant due to cough. These patients were then started on an ARB that turned out to be an acceptable alternative.

C. Incorrect. Beta-blockers, aspirin, and alpha-blockers are not acceptable alternatives to an ACEI.

D. Incorrect. Beta-blockers, aspirin, and alpha-blockers are not acceptable alternatives to an ACEI.